Loading clinical trials...
Loading clinical trials...
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Conditions
Interventions
ABT-493
ABT-530
Locations
42
United States
Digestive Health Specialists of the Southeast /ID# 136725
Dothan, Alabama, United States
Felizarta /ID# 141033
Bakersfield, California, United States
Southern California Res. Ctr. /ID# 141799
Coronado, California, United States
Research & Education, Inc. /ID# 169591
San Diego, California, United States
eStudySite San Diego /ID# 141040
San Diego, California, United States
eStudySite San Diego /ID# 141047
San Diego, California, United States
Start Date
June 22, 2015
Primary Completion Date
October 15, 2019
Completion Date
October 15, 2019
Last Updated
September 21, 2020
NCT06953479
NCT04162938
NCT03135886
NCT05968573
NCT01644903
NCT05368974
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions